Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.

Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.

The present invention disclosed fluoralkenyl compounds of general formula (I);

##STR00001##

wherein; R, R.sup.1, R.sup.2, R.sup.3, A and integers n, m and k are as defined in description. The present invention further discloses use of the compounds of general formula (I) to protect crops by controlling or preventing against undesired phytopathogenic microorganisms such as nematodes and phytopathogenic fungi.

The present invention disclosed fluoralkenyl compounds of general formula (I);

##STR00001##

wherein; R, R.sup.1, R.sup.2, R.sup.3, A and integers n, m and k are as defined in description. The present invention further discloses use of the compounds of general formula (I) to protect crops by controlling or preventing against undesired phytopathogenic microorganisms such as nematodes and phytopathogenic fungi.

The present invention relates to sulfonylureas and sulfonylthioureas comprising as-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with at least one group containing an oxygen atom, and wherein said oxygen atom is attached to the heteroaryl ring via at least two other atoms. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

##STR00001##

The present invention relates to sulfonylureas and sulfonylthioureas comprising as-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with at least one group containing an oxygen atom, and wherein said oxygen atom is attached to the heteroaryl ring via at least two other atoms. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

##STR00001##

The invention relates to a composition comprising a fluorine-containing surfactant having a cationic group, a divalent sulfur-containing group and a fluorinated group, further comprising an anion that corresponds to the cationic group of the fluorine-containing surfactant, the cationic group being an N-alkylated heterocyclic group.

The invention relates to a composition comprising a fluorine-containing surfactant having a cationic group, a divalent sulfur-containing group and a fluorinated group, further comprising an anion that corresponds to the cationic group of the fluorine-containing surfactant, the cationic group being an N-alkylated heterocyclic group.

Methods for fluorinating organic compounds utilizing a novel organic reagent are described herein. The invention further discloses the utility of this reagent for incorporation of the 18 F isotope into hydroxyl group-containing organic molecules for PET imaging studies. Preparation of the reagents is described along with isolable intermediate structures from reaction of the reagent with a hydroxyl group-containing organic molecule.

Methods for fluorinating organic compounds utilizing a novel organic reagent are described herein. The invention further discloses the utility of this reagent for incorporation of the 18 F isotope into hydroxyl group-containing organic molecules for PET imaging studies. Preparation of the reagents is described along with isolable intermediate structures from reaction of the reagent with a hydroxyl group-containing organic molecule.